It is a medication with the same drug as Ozempic, although with a higher dose. It is aimed at patients with obesity or overweight.
Wegovy, the weight loss drug that became popular in hollywood, finally reached the Argentina this Tuesday. The drug marked a before and after in the world in the treatment of obesity and overweight, with demonstrated success in reducing body weight, with Additional benefits for cardiovascular and metabolic health.
The drug it contains is semaglutide, the same as him Ozempic, although in a higher dose: this new drug contains 2.4 milligrams while the other has a dose of 0.25, 0.5 and up to 1 milligram.
The other difference between drugs is that the Ozempic is intended for patients with type 2 diabetes while the Wegovy is especially aimed at people with obesity.
The injection (applied once a week) generates a decrease in appetite and an increase in the feeling of satiety, which facilitates lower calorie consumption and subsequent weight loss. Clinical studies showed that it achieved reductions of up to 20% in body weight and the average loss was 17%.
Starting this Tuesday, the injectable medication produced by the Danish laboratory Nordisk It is now available throughout the country and can be purchased with a doctor’s prescription.
Who is Wegovy suitable for?
The National Administration of Drugs, Food and Medical Technology (ANMAT) approved it in 2023 as a complement to a low-calorie diet and greater physical activity, aimed at adults with obesity or overweight who have at least one weight-related comorbidity such as prediabetes, hypertension, sleep apnea or cardiovascular diseases. These same criteria were used by the United States FDA for its authorization.
It can also be received by adolescents over 12 years of age, although it is indicated only for those with a body mass index (BMI) at the 95th percentile or higher and a weight greater than 60 kg.
According to a statement from Novo Nordisk, “it is the first weekly GLP-1 receptor agonist indicated for the control of body weight in combination with a reduced-calorie diet and increased physical activity“.
In addition, it was detailed that the medication has a 94% similarity to human GLP-1 hormoneand act reducing hunger and increasing feelings of satiety, which helps people eat less and reduce their caloric intake.
Source: Ambito
I am an author and journalist who has worked in the entertainment industry for over a decade. I currently work as a news editor at a major news website, and my focus is on covering the latest trends in entertainment. I also write occasional pieces for other outlets, and have authored two books about the entertainment industry.
